Hester Biosciences Limited has reported a sharp rise in annual profits, driven by higher revenues and improved operating margins, while also expanding its vaccine manufacturing capabilities.
The Ahmedabad-based animal healthcare company said its consolidated net profit for the financial year ending March 2026 rose 99% year-on-year to Rs 57.48 crore, compared with Rs 28.83 crore in the previous financial year.
Revenue from operations increased 7% to Rs 332.60 crore in FY26, up from Rs 311.10 crore a year earlier.
The company’s earnings before interest, taxes, depreciation and amortisation (EBITDA) climbed 53% to Rs 105.65 crore, with EBITDA margins improving to 32% from 22% in FY25.
For the January-to-March quarter, Hester Biosciences reported a significant improvement in profitability. Net profit for the fourth quarter rose 974% year-on-year to Rs 16.55 crore, while revenue grew 22% to Rs 100.11 crore.
The board has recommended a dividend of Rs 11 per equity share for FY26, subject to shareholder approval at the company’s upcoming annual general meeting.
During the quarter, the company also completed the capitalisation of its Biosafety Level 3 (BSL-3) facility, part of a broader expansion programme aimed at strengthening manufacturing capacity and research infrastructure.
Hester Biosciences said it is additionally undertaking optimisation of certain manufacturing facilities to improve operational efficiency and reduce costs as production scales up.
The company also received marketing and manufacturing licences for its H9N2 Avian Influenza vaccine during the quarter. The approval is expected to strengthen its poultry vaccine portfolio at a time when demand for preventive animal healthcare products continues to grow.
Hester Biosciences manufactures vaccines and animal health products for poultry, livestock and companion animals, with operations spanning domestic and international markets.
